sigma-tau Industrie Farmaceutiche Riunite S.p.A. Research and Development, Pomezia, Rome, Italy.
Antimicrob Agents Chemother. 2012 Dec;56(12):6400-2. doi: 10.1128/AAC.01000-12. Epub 2012 Sep 24.
This study evaluated the pharmacological activity of PTX3, administered in combination with voriconazole, in a rat model of pulmonary aspergillosis. The data indicated additive therapeutic activities of these compounds, as demonstrated by the amelioration of respiratory function changes, reduction of lung fungal burden, and increased survival. Overall, we provide clear evidence that the combination of PTX3 with a suboptimal dose of voriconazole might represent a therapeutic option under those clinical conditions where the use of voriconazole alone is not warranted for efficacy and tolerability reasons.
本研究评估了 PTX3 与伏立康唑联合用药在肺曲霉病大鼠模型中的药理活性。数据表明，这些化合物具有相加的治疗活性，表现为呼吸功能变化的改善、肺部真菌负荷的减少和生存率的提高。总的来说，我们提供了明确的证据，表明 PTX3 与伏立康唑亚治疗剂量的联合使用可能代表了一种治疗选择，适用于那些由于疗效和耐受性原因单独使用伏立康唑不被推荐的临床情况。
